5-HT₃-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatmentAAPRO, Matti.Oncology. 2005, Vol 69, Num 2, pp 97-109, issn 0030-2414, 13 p.Article

Breast cancer : not a single diseaseAAPRO, Matti.European journal of cancer. Supplement (1990). 2006, Vol 4, Num 4, pp 1-3, issn 1359-6349, 3 p.Article

SIOG (International Society of Geriatric Oncology) and anthracycline use in the elderlyAAPRO, Matti.European journal of cancer. Supplement (1990). 2011, Vol 9, Num 2, pp 30-35, issn 1359-6349, 6 p.Article

How do we manage patients with refractory or breakthrough emesis?AAPRO, Matti S.Supportive care in cancer. 2002, Vol 10, Num 2, pp 106-109, issn 0941-4355Article

Will new agents improve outcomes in the adjuvant setting?AAPRO, Matti S.Seminars in oncology. 1999, Vol 26, Num 1, issn 0093-7754, 31 p., SUP3Serial Issue

Oncologie = OncologyAAPRO, Matti S.Revue médicale suisse. 2009, Vol 5, Num 189, issn 1660-9379, 322-327 [5 p.]Article

5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis : Can we safely reduce the dose of administered agents?AAPRO, Matti; BLOWER, Peter.Cancer. 2005, Vol 104, Num 1, pp 1-13, issn 0008-543X, 13 p.Article

Chemotherapy-induced emesis in elderly cancer patients : The role of 5-HT₃-receptor antagonists in the first 24 hoursAAPRO, Matti; JOHNSON, Judi.Gerontology (Basel). 2005, Vol 51, Num 5, pp 287-296, issn 0304-324X, 10 p.Article

Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancerAAPRO, Matti S; VON MINCKWITZ, Gunter.European journal of cancer. Supplement (1990). 2008, Vol 6, Num 10, pp 3-11, issn 1359-6349, 9 p.Conference Paper

Moving Forward with New Data and Approaches: A Fresh Look at Anthracyclines in Breast Cancer. Summary of a workshop held in September 2010AMADORI, Dino; AAPRO, Matti.European journal of cancer. Supplement (1990). 2011, Vol 9, Num 2, issn 1359-6349, 44 p.Serial Issue

Adjuvant breast cancer therapy : Current status and future strategies-growth kinetics and the improved drug therapy of breast cancerNORTON, L.Seminars in oncology. 1999, Vol 26, Num 1, pp 1-4, issn 0093-7754, SUP3Article

New paradigms in the treatment of advanced breast cancerAAPRO, Matti; GOLDHIRSCH, Aron.Seminars in oncology. 1998, Vol 25, Num 5, issn 0093-7754, 35 p., SUP12Serial Issue

Evolving treatment strategies for anaemia in cancer: Experience with epoetin betaAAPRO, Matti; SAN MIGUEL, Jésus.Oncology. 2004, Vol 67, pp 17-22, issn 0030-2414, 6 p., SUP1Conference Paper

Is there a place for dose-dense weekly schedules of the taxoids ?LÖFFLER, T. M.Seminars in oncology. 1998, Vol 25, Num 5, pp 32-34, issn 0093-7754, SUP12Article

Overcoming challenges associated with chemotherapy treatment in the senior adult populationDROZ, Jean-Pierre; AAPRO, Matti; BALDUCCI, Lodovico et al.Critical reviews in oncology/hematology. 2008, Vol 68, issn 1040-8428, S1-S8, SUP1Article

Comparative activity of antiemetic drugsJORDAN, Karin; SCHMOLL, Hans J; AAPRO, Matti S et al.Critical reviews in oncology/hematology. 2007, Vol 61, Num 2, pp 162-175, issn 1040-8428, 14 p.Article

Combining new agents with anthracyclines in metastatic breast cancer : An overview of recent findingsAAPRO, M. S.Seminars in oncology. 1999, Vol 26, Num 1, pp 17-21, issn 0093-7754, SUP3Article

Anthracyclines in the adjuvant treatment of breast cancer: state of the artFORNIER, Monica N.European journal of cancer. Supplement (1990). 2011, Vol 9, Num 2, pp 5-10, issn 1359-6349, 6 p.Article

Managing myelotoxicities of breast cancer chemotherapies : what is the role for G-CSF?CAMERON, David; AAPRO, Matti.European journal of cancer. Supplement (1990). 2008, Vol 6, Num 2, pp 17-23, issn 1359-6349, 7 p.Conference Paper

Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy : A preliminary report of the randomized phase III trialAAPRO, M.Seminars in oncology. 1998, Vol 25, Num 5, pp 7-11, issn 0093-7754, SUP12Article

Epoetin beta (NeoRecormon®): energising anaemia management for patients with cancer: highlights from the proceedings of a Roche-Sponsored Symposium, Madrid, Spain, May 7-9, 2004AAPRO, Matti; SAN MIGUEL, Jes´us.Oncology. 2004, Vol 67, issn 0030-2414, 25 p., SUP1Conference Proceedings

What can be expected from the next generation of adjuvant breast cancer treatment?PICCART-GEBHART, M.Seminars in oncology. 1999, Vol 26, Num 1, pp 22-25, issn 0093-7754, SUP3Article

Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer : A literature surveyPARIDAENS, R.Seminars in oncology. 1998, Vol 25, Num 5, pp 3-6, issn 0093-7754, SUP12Article

Case histories: breast cancerGENNARI, Alessandra; PIETRI, Elisabetta; AMADORI, Dino et al.European journal of cancer. Supplement (1990). 2011, Vol 9, Num 2, pp 36-42, issn 1359-6349, 7 p.Article

New erythropoietic proteins: Rationale and clinical dataÖSTERBORG, Anders.Seminars in oncology. 2004, Vol 31, Num 3, pp 12-18, issn 0093-7754, 7 p., SUP8Conference Paper